Association Between Stroke Subtype and Outcomes of Edaravone Dexborneol: A Subgroup Analysis of the EXPAND (Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke) Study

Background The effectiveness of edaravone dexborneol among acute ischemic stroke subtypes remains unclear. We evaluated its association with clinical outcomes by stroke subtype. Methods This secondary analysis of the prospective EXPAND (Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke) study included patients with acute ischemic stroke treated at 72 Chinese stroke centers from December 2022 to October 2023. Patients were classified as having large artery atherosclerosis (LAA) or non‐LAA stroke and grouped by edaravone dexborneol use. Primary outcomes were 90‐day modified Rankin Scale (mRS) scores of 0 or 1 and 0 to 2 and ordinal mRS shift. Safety outcomes were 90‐day mortality, intracranial hemorrhage, and in‐hospital adverse events. Results Among 4401 patients, 1061 (24.1%) had LAA and 3340 (75.9%) had non‐LAA stroke; the median age was 65 years, and 66.8% were men. Edaravone dexborneol was associated with improved 90‐day functional outcomes in the non‐LAA group, including higher odds of achieving mRS 0 or 1 (adjusted odds ratio [aOR], 1.25 [95% CI, 1.06–1.47]), mRS 0 to 2 (aOR, 1.40 [95% CI, 1.15–1.71]), and a favorable mRS shift (aOR, 1.28 [95% CI, 1.12–1.46]; all P <0.05). No significant functional benefit was observed in the LAA group of mRS 0 or 1 (aOR, 0.91; P =0.50), mRS 0 to 2 (aOR, 0.88; P =0.43), or mRS shift (aOR, 0.92; P =0.50). Significant interactions were observed between edaravone dexborneol and stroke subtype ( P for interaction=0.03 for mRS 0 or 1, P =0.005 for mRS 0 to 2, and P =0.009 for favorable mRS shift). Safety outcomes were comparable between treatment groups. Conclusions Edaravone dexborneol was associated with improved 90‐day functional outcomes in non‐LAA but not LAA stroke.

Authors

Institutions

Publication Details

Journal
Journal of the American Heart Association
Published
2026-11-12
DOI
https://doi.org/10.1161/jaha.125.048691
Primary Topic
Acute Ischemic Stroke Management
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association Between Stroke Subtype and Outcomes of Edaravone Dexborneol: A Subgroup Analysis of the EXPAND (Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke) Study

­ Raynald, Gaoting Ma, 王剑超, Thanh Ngoc Nguyen et al.
Journal of the American Heart Association
Acute Ischemic Stroke Management
article

Association Between Stroke Subtype and Outcomes of Edaravone Dexborneol: A Subgroup Analysis of the EXPAND (Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke) Study

­ Raynald, Gaoting Ma, 王剑超, Thanh Ngoc Nguyen, Yingting Zuo, Jie Pan, Zhiwei Song, Mohammad Firdaus, Junjie Xu, Yanfei Shao, Jichao Qiu, Jin Hu, EXPAND investigators, Qian Zhang
article en

Abstract

Background The effectiveness of edaravone dexborneol among acute ischemic stroke subtypes remains unclear. We evaluated its association with clinical outcomes by stroke subtype. Methods This secondary analysis of the prospective EXPAND (Effectiveness and Safety of Edaravone Dexborneol in Acute Ischemic Stroke) study included patients with acute ischemic stroke treated at 72 Chinese stroke centers from December 2022 to October 2023. Patients were classified as having large artery atherosclerosis (LAA) or non‐LAA stroke and grouped by edaravone dexborneol use. Primary outcomes were 90‐day modified Rankin Scale (mRS) scores of 0 or 1 and 0 to 2 and ordinal mRS shift. Safety outcomes were 90‐day mortality, intracranial hemorrhage, and in‐hospital adverse events. Results Among 4401 patients, 1061 (24.1%) had LAA and 3340 (75.9%) had non‐LAA stroke; the median age was 65 years, and 66.8% were men. Edaravone dexborneol was associated with improved 90‐day functional outcomes in the non‐LAA group, including higher odds of achieving mRS 0 or 1 (adjusted odds ratio [aOR], 1.25 [95% CI, 1.06–1.47]), mRS 0 to 2 (aOR, 1.40 [95% CI, 1.15–1.71]), and a favorable mRS shift (aOR, 1.28 [95% CI, 1.12–1.46]; all P <0.05). No significant functional benefit was observed in the LAA group of mRS 0 or 1 (aOR, 0.91; P =0.50), mRS 0 to 2 (aOR, 0.88; P =0.43), or mRS shift (aOR, 0.92; P =0.50). Significant interactions were observed between edaravone dexborneol and stroke subtype ( P for interaction=0.03 for mRS 0 or 1, P =0.005 for mRS 0 to 2, and P =0.009 for favorable mRS shift). Safety outcomes were comparable between treatment groups. Conclusions Edaravone dexborneol was associated with improved 90‐day functional outcomes in non‐LAA but not LAA stroke.

Journal of the American Heart Association
Boston Medical Center (US), Capital Medical University (CN), Jiaxing University (CN), Xuan Wu Hospital of the Capital Medical University (CN), County Hospital (GB), Dharmais Cancer Hospital (ID)
Good health and well-being
Acute Ischemic Stroke Management
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon